DBV Technologies Submits BLA for VIASKIN Peanut and Outlines Cash Runway Through 2027
DBV Technologies (DBVT) has officially submitted its Biologics License Application (BLA) for the VIASKIN Peanut patch intended for children aged 4 to 7 years. To optimize the FDA review process, management is utilizing a sequential filing strategy rather than submitting multiple complex applications simultaneously, which they believe will prevent regulatory bottlenecks. The company faces a significant operational hurdle regarding its contract manufacturer, Fareva Amboise, which recently received an FDA Warning Letter for quality management issues. DBV is currently working to remediate these findings to ensure readiness for upcoming pre-approval inspections. Financially, DBV reported $165.7 million in cash and cash equivalents at the end of the third quarter. Management has implemented a milestone-based spending plan designed to extend the company's cash runway into the third quarter of 2027, balancing commercial launch preparations with capital discipline.

Tickers: $DBVT
Topics: Biologics License Application Cash Runway Contract Manufacturing FDA Approval Process